CytoMed Therapeutics Future Growth
Future criteria checks 1/6
CytoMed Therapeutics is forecast to grow earnings and revenue by 10.2% and 19.7% per annum respectively while EPS is expected to grow by 6.7% per annum.
Key information
10.2%
Earnings growth rate
6.7%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | 19.7% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 10 Oct 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 1 | -3 | N/A | -2 | 1 |
| 12/31/2024 | 1 | -2 | N/A | -2 | 1 |
| 6/30/2024 | 0 | -3 | -4 | -3 | N/A |
| 3/31/2024 | 0 | -4 | -3 | -3 | N/A |
| 12/31/2023 | 1 | -4 | -3 | -3 | N/A |
| 9/30/2023 | 1 | -4 | -3 | -3 | N/A |
| 6/30/2023 | 1 | -4 | -3 | -3 | N/A |
| 3/31/2023 | 0 | -4 | -2 | -2 | N/A |
| 12/31/2022 | 0 | -3 | -2 | -1 | N/A |
| 9/30/2022 | 0 | -3 | -2 | -1 | N/A |
| 6/30/2022 | 0 | -2 | -3 | -2 | N/A |
| 3/31/2022 | 0 | -2 | -2 | -2 | N/A |
| 12/31/2021 | 0 | -2 | -2 | -2 | N/A |
| 9/30/2021 | 0 | -2 | -2 | -1 | N/A |
| 6/30/2021 | 0 | -2 | -1 | -1 | N/A |
| 3/31/2021 | 0 | -2 | -1 | -1 | N/A |
| 12/31/2020 | 0 | -2 | -1 | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GDTC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GDTC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GDTC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GDTC's revenue (19.7% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: GDTC's revenue (19.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GDTC's Return on Equity is forecast to be high in 3 years time